Strategic Asset Settlement Recent asset sale to IMAC Holdings with debt resolution suggests a pivot in strategic direction while preserving precision medicine capabilities. Potential sales lever: explore licensing or service partnerships around Theralink's phosphoprotein-based assay technology to IMAC or similar oncology-focused distributors seeking to expand their precision medicine offerings.

Pan-tumor Expansion Opportunity Theralink is developing a second pan-tumor assay beyond breast cancer, targeting multiple solid tumors. Sales angle: position to biopharma clients and CROs seeking multiplexed phosphoprotein profiling to support broad oncology trials, especially for companies pursuing tumor-agnostic or multi-tumor therapies.

Clinical Decision Support The core value proposition centers on quantifying phosphorylation states to guide treatment decisions. Upsell potential: offer integrated companion diagnostics services or data interpretation support to oncologists and trial sponsors who need actionable biomarker readouts to optimize patient stratification.

Leadership and Commercialization Recent leadership hires focused on commercialization indicate a push to scale market reach. Sales play: engage biotech and pharma partners through strategic alliances, co-development of assay panels, and outbound campaigns highlighting faster path to patient-tailored therapies.

Financial and Growth Signals Revenue range and modest funding suggest a lean, growth-ready organization with room for partner-driven revenue. Sales tactic: propose collaborative funding models, milestone-based deployments, and joint benchmarking programs with potential customers to minimize upfront investment while validating commercial impact.